Home › Research › Treatments
The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease
Doraiswamy PM, Kaiser L, Bieber F, Garman RL.. Alzheimer disease and associated disorders, 2001-10-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Purpose To evaluate the psychometric properties and patterns of decline on the total score and item scores of the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) in patients with Alzheimer Disease (AD). Methods We analyzed data from 536 AD outpatients randomized to the placebo group in two identical 26-week multicenter drug trials. Results Mean deterioration at week 26 on the ADAS-Cog total score for subjects with moderate dementia was 84% greater than that for those with milder severity ( p Conclusions There is a relationship between baseline severity and magnitude of cognitive decline. In 6-month trials, measurement error makes a substantial contribution to the variance in ADAS-Cog change scores. Sensitivity to intervention effects will therefore depend both on the variability and magnitude of change. Such data must be considered when designing future trials to minimize measurement error variability and increase sensitivity for specific populations.
What this study adds
Evidence grade: High
This analysis of 536 patients with Alzheimer's disease in placebo groups of drug trials found that those with moderate dementia declined 84% more on the ADAS-Cog total score over 26 weeks than those with milder dementia. Its stated limit: This analysis used only the untreated placebo arms of two specific trials, so how it generalizes to other patient populations or longer time periods is not addressed.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Doraiswamy, P. M., Kaiser, L., Bieber, F., & Garman, R. L. (2001). The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer disease and associated disorders. https://doi.org/10.1097/00002093-200110000-00003
Vancouver
Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer disease and associated disorders. 2001. doi:10.1097/00002093-200110000-00003. PMID: 11723368.
BibTeX
@article{doraiswamy2001-11723368,
author = {Doraiswamy, P. M. and Kaiser, L. and Bieber, F. and Garman, R. L.},
title = {{The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease}},
journal = {Alzheimer disease and associated disorders},
year = {2001},
doi = {10.1097/00002093-200110000-00003},
pmid = {11723368},
url = {https://doi.org/10.1097/00002093-200110000-00003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Mean deterioration at week 26 on the ADAS-Cog total score for subjects with moderate dementia was 84% greater than that for those with milder severity ( p Conclusions There is a relationship between baseline severity and magnitude of cognitive decline.
Why it matters
This analysis of 536 patients with Alzheimer's disease in placebo groups of drug trials found that those with moderate dementia declined 84% more on the ADAS-Cog total score over 26 weeks than those with milder dementia. The study also found that measurement error substantially contributes to score changes, which is important for designing future trials but does not test any treatment.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
Limitations
This analysis used only the untreated placebo arms of two specific trials, so how it generalizes to other patient populations or longer time periods is not addressed.
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 39 of the 96 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2001 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 106 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.9 citations a year over 27 year(s) since 2001 |
| Impact for its field and year | 2 / 6 | Cited 2.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Robert L. Garman holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Duke Medical Center: institution h-index 1,255 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11723368) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 39 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 39 of the 96 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.